The Group’s Australian manufacturing facility, Contract Manufacturing & Packaging Services (CMPS) Pty Ltd, located in New South Wales, has served as a trusted pharmaceutical manufacturing hub for more than two decades. Operating under the stringent regulatory oversight of the Therapeutic Goods Administration (TGA), CMPS manufactures and packages pharmaceutical products for Australia and more than 45 countries worldwide, providing technical expertise, regulatory support, and international manufacturing standards across the Zifam network.

The Group’s manufacturing partnerships in India strengthen production capacity across a broad range of pharmaceutical dosage forms while supporting international WHO-GMP quality standards. This strategic manufacturing capability enhances supply reliability, manufacturing flexibility, and access to global pharmaceutical technologies for regional and international markets.

Established in 2015, Zifam Pyrex Myanmar Co., Ltd. represents the Group’s strategic manufacturing investment in Myanmar. Located within the Thilawa Special Economic Zone (SEZ), the facility manufactures Beta-Lactam antibiotics and General Oral Solid Dosage products under WHO-GMP standards, supported by an ISO/IEC 17025:2017 accredited Quality Control Laboratory. As the newest manufacturing facility within the Group, Zifam Pyrex Myanmar combines global pharmaceutical expertise with local manufacturing excellence to support Myanmar’s healthcare system and expanding international business partnerships.

Together, these manufacturing facilities form an integrated pharmaceutical network that enables knowledge sharing, technology transfer, regulatory excellence, and sustainable manufacturing growth. This global collaboration strengthens our ability to provide contract manufacturing opportunities, reliable pharmaceutical supply, and long-term partnerships while remaining true to our corporate commitment—Committed to Excellence.